Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Weight Gain*/drug effects ; Heterocyclic Compounds, 3-Ring*/adverse effects ; Heterocyclic Compounds, 3-Ring*/therapeutic use ; Heterocyclic Compounds, 3-Ring*/administration & dosage ; HIV Infections*/drug therapy ; HIV Infections*/physiopathology ; Tenofovir*/adverse effects ; Tenofovir*/therapeutic use ; Tenofovir*/administration & dosage ; Blood Pressure*/drug effects ; Lamivudine*/adverse effects ; Lamivudine*/therapeutic use ; Lamivudine*/administration & dosage ; Anti-HIV Agents*/adverse effects ; Anti-HIV Agents*/therapeutic use; Humans ; Pyridones ; Oxazines ; Female ; Piperazines ; Male ; Adult ; Uganda ; Prospective Studies ; Middle Aged
    • Abstract:
      Competing Interests: The authors have declared that no competing interests exist.
      Background: Most people living with HIV in low and middle-income countries are taking fixed dose combination tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD). Dolutegravir use has been associated with weight gain, a known risk factor for hypertension. We aimed to determine if weight gain in Ugandan anti-retroviral therapy (ART) naïve patients on TLD correlated with increase in blood pressure.
      Methods: We analyzed data from the 'Glucose metabolism changes in Ugandan persons with HIV (PLHIV) on Dolutegravir (GLUMED)' study which was a prospective cohort study with ART naïve persons with HIV ≥ 18 years followed up on TLD over 48 weeks. A scatter plot with 95% confidence intervals and regression line illustrating the relationship between weight change and mean arterial pressure (MAP) change from baseline to 48 weeks was created. To further examine the effect of weight change on MAP, we performed a linear regression analysis, with MAP change as the dependent variable and weight change as the independent variable.
      Results: Of the 220 patients' data analyzed, 129 (58.6%) were female, the median baseline age was 31 years (interquartile range (IQR): 27.0-38.0), the median baseline CD4 cell count was 319 cells/mm3 (IQR 160.0-524.0). The median weight gain over 48 weeks was 3.0 (IQR: -0.1-6.3). We found a moderate positive linear relationship between weight gain and MAP over 48 weeks. For every increase in weight of 1 kg over 48 weeks, there was an adjusted increase in MAP by 0.62mmHG.
      Conclusion: We provide additional evidence to suggest that the noticed weight gain after starting dolutegravir based ART may be associated with a heightened risk of incident hypertension.
      (Copyright: © 2025 Amutuhaire et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      BMC Infect Dis. 2024 Jul 29;24(1):746. (PMID: 39075383)
      Cureus. 2023 Apr 12;15(4):e37467. (PMID: 37187665)
      Drug Des Devel Ther. 2015 Jul 07;9:3547-55. (PMID: 26185421)
      PLoS One. 2013;8(4):e59768. (PMID: 23577074)
      AIDS Res Ther. 2023 Mar 13;20(1):15. (PMID: 36915103)
      J Infect Chemother. 2021 Jul;27(7):949-956. (PMID: 33663931)
      SAGE Open Med. 2024 Jun 13;12:20503121241260613. (PMID: 38881592)
      EClinicalMedicine. 2023 Feb 06;57:101836. (PMID: 36816348)
      Ann Med. 2023;55(2):2242250. (PMID: 37531412)
      South Afr J HIV Med. 2023 May 15;24(1):1500. (PMID: 37293606)
      AIDS Res Ther. 2023 Sep 9;20(1):65. (PMID: 37689695)
      Circ Res. 2015 Mar 13;116(6):991-1006. (PMID: 25767285)
      Braz J Infect Dis. 2023 Sep-Oct;27(5):102807. (PMID: 37788801)
      Lancet HIV. 2024 May;11(5):e321-e332. (PMID: 38621392)
      Circulation. 2019 Mar 5;139(10):e56-e528. (PMID: 30700139)
      Int J Hypertens. 2021 Feb 10;2021:6657003. (PMID: 33628485)
      J Korean Med Sci. 2013 Jul;28(7):990-7. (PMID: 23853480)
      HIV Med. 2017 Apr;18(4):256-266. (PMID: 27578404)
      J Int AIDS Soc. 2019 Jul;22(7):e25364. (PMID: 31353831)
      Virtual Mentor. 2010 Mar 01;12(3):202-6. (PMID: 23140869)
      Clin Kidney J. 2023 Nov 13;17(1):sfad282. (PMID: 38186879)
      Hypertens Res. 2010 May;33(5):386-93. (PMID: 20442753)
    • Accession Number:
      DKO1W9H7M1 (dolutegravir)
      0 (Heterocyclic Compounds, 3-Ring)
      0 (Pyridones)
      0 (Oxazines)
      0 (Piperazines)
      99YXE507IL (Tenofovir)
      2T8Q726O95 (Lamivudine)
      0 (Anti-HIV Agents)
    • Publication Date:
      Date Created: 20250611 Date Completed: 20250611 Latest Revision: 20250614
    • Publication Date:
      20250614
    • Accession Number:
      PMC12157303
    • Accession Number:
      10.1371/journal.pone.0325020
    • Accession Number:
      40498733